언어 선택

Bridging ELISA Kits

The core competitiveness of bispecific antibodies (bsAbs) lies in their ability to simultaneously engage two distinct targets with a single molecule, enabling novel mechanisms of action and unique clinical benefits beyond those of monoclonal antibodies or combination therapies. The target-binding capability is a critical determinant of a bsAb's therapeutic efficacy, safety, and the success of its development. The affinity and specificity for both targets are fundamental to triggering key mechanisms, including immune cell redirection and synergistic regulation of signaling pathways, while minimizing off-target effects and providing a robust safety foundation for clinical translation.

An effective evaluation of bsAb binding must consider both the properties of individual targets and the dual-target bridging effect. This capability serves as an essential quality control metric throughout the drug development lifecycle: enabling early-stage screening to eliminate weak candidates, ensuring batch-to-batch consistency during manufacturing, and supporting regulatory submissions with standardized data.

However, accurately assessing the target-binding activity of bsAbs presents significant challenges at each stage of development.

Assessment of BsAb Target-Binding Activity: Challenges vs. Ideal Solutions

Traditional Challenges	Features of Ideal Solutions
High risk of functional misjudgment Single-target assays cannot replicate true “bridging” activity, often leading to misinterpretation of candidates in early screening and inefficient resource use.	Direct assessment of authentic bridging activity Quantitatively evaluates a bsAb’s simultaneous engagement of both targets, ensuring results accurately reflect biological function and reducing early-stage misjudgment.
Poor data consistency In-house methods vary in antigen source, coating conditions, etc., resulting in significant batch-to-batch variability and weak comparability for regulatory submission.	Standardized system with long-term comparability Highly standardized methods ensure stable and comparable data across time, batches, and operators, supporting process optimization and regulatory submissions.
Long method development cycles Multiple assay systems must be developed separately, consuming significant time and personnel, slowing overall project progress.	Ready-to-use solutions for high efficiency Integrated and simplified workflows support high-throughput applications, maintaining data quality while significantly improving efficiency.

Traditional Challenges

Features of Ideal Solutions

High risk of functional misjudgment

Single-target assays cannot replicate true “bridging” activity, often leading to misinterpretation of candidates in early screening and inefficient resource use.

Direct assessment of authentic bridging activity

Quantitatively evaluates a bsAb’s simultaneous engagement of both targets, ensuring results accurately reflect biological function and reducing early-stage misjudgment.

Poor data consistency

In-house methods vary in antigen source, coating conditions, etc., resulting in significant batch-to-batch variability and weak comparability for regulatory submission.

Standardized system with long-term comparability

Highly standardized methods ensure stable and comparable data across time, batches, and operators, supporting process optimization and regulatory submissions.

Long method development cycles

Multiple assay systems must be developed separately, consuming significant time and personnel, slowing overall project progress.

Ready-to-use solutions for high efficiency

Integrated and simplified workflows support high-throughput applications, maintaining data quality while significantly improving efficiency.

Selecting the scientific evaluation method and accurately assessing target-binding capability are crucial for streamlining bsAb development and accelerating the translation of effective therapeutics from the lab to the clinic. Leveraging advanced protein development platforms and a rigorous end-to-end quality control system, ACROBiosystems has meticulously developed the Bridging ELISA Kits, providing standardized and efficient detection solutions for bsAb drug development.

Schematic Workflow of the Bridging ELISA Kits

Schematic Workflow of the Bridging ELISA Kits

Product Advantages

Simultaneous dual-target assessment for real biological activity

Designed based on the bridging ELISA principle, the kit evaluates bsAb binding to both targets in a single system. Results have been validated with marketed drugs, ensuring accuracy and reliability.

Easy, efficient operation for high-throughput screening

Pre-coated plates eliminate manual coating and complex method development, simplifying workflows and enabling high-throughput applications to boost R&D efficiency.

Rigorous quality control ensures batch consistency

Strict QC systems provide excellent batch-to-batch reproducibility, ensuring stable and comparable data for long-term research and quality control.

Comprehensive validation supports regulatory submission

Includes full validation data and standard protocols, facilitating rapid in-house method development and providing strong support for regulatory filings.

High performance with cost efficiency

Delivers excellent detection performance while reducing material and time costs, maximizing R&D value.

Customizable to meet specific needs

Customized development services are available for specific target combinations, precisely meeting diverse and personalized requirements across various bsAb R&D scenarios.

Service Timeline

Service	Deliverables	Timeline
Method Development:	1. Method Development Data 2. Protocol	2-3 Weeks
Method Validation	1. Method Validation Report	4-5 Weeks
Kit Production	1. Kit Components 2. COA 3. Data Sheet	2-3 Weeks

Service

Deliverables

Timeline

Method Development:

1. Method Development Data

2. Protocol

2-3 Weeks

Method Validation

1. Method Validation Report

4-5 Weeks

Kit Production

1. Kit Components

2. COA

3. Data Sheet

2-3 Weeks

Inquire Now!

Product List

Cat. No.	Molecule	Product Description	예약 주문/주문
BIS-A001	BCMA & CD3E	Bispecific Human BCMA & CD3E Bridging ELISA Kit	주문
BIS-A002	CD19 & CD3E	Bispecific Human CD19 & CD3 Bridging ELISA Kit	주문
BIS-A003	CD20 & CD3E	Bispecific Human CD20 & CD3E Bridging ELISA Kit	주문
BIS-A004	Claudin-18.2 & CD3E	Bispecific Human Claudin-18.2 & CD3E Bridging ELISA Kit	주문
BIS-A005	DLL3 & CD3E	Bispecific Human DLL3 & CD3E Bridging ELISA Kit	주문
BIS-A006	hEGFR & hCMET	Bispecific Human EGFR & c-Met Bridging ELISA Kit	주문
BIS-A007	Kallikrein 2 & CD3	Bispecific Human KLK2 & CD3 Bridging ELISA Kit	주문
BIS-A008	PD-1 & VEGFA	Bispecific Human PD-1 & VEGFA Bridging ELISA Kit	주문
BIS-A009	PD-L1 & VEGFA	Bispecific Human PD-L1 & VEGFA Bridging ELISA Kit	주문

Validation Data

Detection of Anti-BCMA and CD3 bsAb Using Bridging ELISA Kits

Bispecific Human BCMA & CD3E Bridging ELISA Kit (Cat. No. BIS-A001) can specifically identify Anti-BCMA & CD3 Antibodies, with linear range of 0.010-0.317 nM.

Accelerated Stability Testing of Bridging ELISA Kits

Bispecific Human BCMA & CD3E Bridging ELISA Kit (Cat. No. BIS-A001) was subjected to accelerated testing at 37℃ for 0 days and 14 days, and the RSD of EC50 was 11%.